{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:22:00Z","timestamp":1790011320788,"version":"4.0.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stenotrophomonas maltophilia causes severe infections with limited treatment options. Aztreonam-avibactam demonstrates in vitro activity against this important pathogen with an MIC90 of 4\/4\u2005mg\/L, but the efficacy of this agent is unknown. Herein, we used the neutropenic thigh infection model to assess in vivo efficacy against S. maltophilia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>S. maltophilia isolates (n\u200a=\u200a27) resistant to aztreonam (MIC \u200a\u226564\u2005mg\/L) and with aztreonam-avibactam MICs between 2\/4 and &amp;gt;16\/4\u2005mg\/L were examined using a neutropenic murine thigh infection model. Pharmacokinetic studies were performed for the development of a human-simulated regimen (HSR) of aztreonam-avibactam (1.5\u20130.5\u2005g q6h, 3h infusion) to mimic the human free plasma exposure profile. Efficacy of the aztreonam-avibactam HSR was defined as \u200a\u22651 log10 cfu\/thigh reduction at 24\u2005h compared with baseline bacterial burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among investigated isolates, the mean baseline bacterial burden in the model was 6.22\u200a\u00b1\u200a0.16 log10 cfu\/thigh. Without treatment, isolates grew on average to 7.81\u200a\u00b1\u200a0.44 log10 cfu\/thigh at 24\u2005h. With aztreonam-avibactam HSR administration, 78% (7\/9), 67% (6\/9), 29% (2\/7) and 0% (0\/2) reached \u22651 log10 cfu\/thigh reduction at MICs of 2\/4, 4\/4, 8\/4 and \u226516\/4\u2005mg\/L, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Aztreonam-avibactam HSR demonstrated in vivo efficacy against the majority of S. maltophilia isolates with MIC \u22644\/4\u2005mg\/L in a neutropenic murine thigh infection model. These results provide decision support to standards development organizations for determination of susceptibility breakpoints for aztreonam-avibactam against S. maltophilia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf388","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:09:12Z","timestamp":1759320552000},"page":"3431-3437","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of human-simulated aztreonam-avibactam against\n                    <i>Stenotrophomonas maltophilia<\/i>\n                    in the neutropenic murine thigh infection model"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9359-0930","authenticated-orcid":false,"given":"Yakun","family":"Fu","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6467-1806","authenticated-orcid":false,"given":"Aliaa","family":"Fouad","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna F","family":"Roenfanz","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L","family":"Kuti","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2025120206223064000_dkaf388-B1","doi-asserted-by":"publisher","first-page":"e0003019","DOI":"10.1128\/CMR.00030-19","article-title":"Advances in the microbiology of Stenotrophomonas maltophilia","volume":"34","author":"Brooke","year":"2021","journal-title":"Clin Microbiol Rev"},{"key":"2025120206223064000_dkaf388-B2","doi-asserted-by":"publisher","first-page":"dlac040","DOI":"10.1093\/jacamr\/dlac040","article-title":"Clinical challenges treating Stenotrophomonas maltophilia infections: an update","volume":"4","author":"Mojica","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2025120206223064000_dkaf388-B3","doi-asserted-by":"publisher","first-page":"ofaa141","DOI":"10.1093\/ofid\/ofaa141","article-title":"The burden of bloodstream infections due to Stenotrophomonas maltophilia in the United States: a large, retrospective database study","volume":"7","author":"Cai","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025120206223064000_dkaf388-B4","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1093\/jac\/dky279","article-title":"Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015\u201317)","volume":"73","author":"Sader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025120206223064000_dkaf388-B5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/phar.2828","article-title":"Steno-sphere: navigating the enigmatic world of emerging multidrug-resistant Stenotrophomonas maltophilia","volume":"43","author":"Kunz Coyne","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2025120206223064000_dkaf388-B6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025120206223064000_dkaf388-B7","volume-title":"Emblaveo (aztreonam and avibactam)","year":"2024"},{"key":"2025120206223064000_dkaf388-B8","volume-title":"Emblaveo (aztreonam and avibactam)","year":"2025"},{"key":"2025120206223064000_dkaf388-B9","doi-asserted-by":"publisher","first-page":"e00297-20","DOI":"10.1128\/AAC.00297-20","article-title":"Activity of aztreonam in combination with avibactam, clavulanate, relebactam, and vaborbactam against multidrug-resistant Stenotrophomonas maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223064000_dkaf388-B10","doi-asserted-by":"publisher","first-page":"e01433-20","DOI":"10.1128\/AAC.01433-20","article-title":"Antimicrobial activity of aztreonam-avibactam and comparator agents when tested against a large collection of contemporary Stenotrophomonas maltophilia isolates from medical centers worldwide","volume":"64","author":"Sader","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223064000_dkaf388-B11","doi-asserted-by":"publisher","first-page":"e0069324","DOI":"10.1128\/aac.00693-24","article-title":"Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-beta-lactamase-producing carbapenem-resistant Gram-negative bacilli","volume":"68","author":"Tao","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223064000_dkaf388-B12","doi-asserted-by":"publisher","first-page":"e0012425","DOI":"10.1128\/aac.00124-25","article-title":"Antimicrobial susceptibility of Stenotrophomonas maltophilia from United States medical centers (2019\u20132023)","volume":"69","author":"Sader","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223064000_dkaf388-B13","doi-asserted-by":"publisher","first-page":"107803","DOI":"10.1016\/j.ijid.2025.107803","article-title":"Antimicrobial susceptibility of clinical isolates of Stenotrophomonas maltophilia from Europe, Asia, and Latin America (2018\u20132023)","volume":"153","author":"Sader","year":"2025","journal-title":"Int J Infect Dis"},{"key":"2025120206223064000_dkaf388-B14","author":"CLSI"},{"key":"2025120206223064000_dkaf388-B15","author":"CLSI"},{"key":"2025120206223064000_dkaf388-B16","doi-asserted-by":"publisher","first-page":"e01950-24","DOI":"10.1128\/aac.01950-24","article-title":"Simultaneous population pharmacokinetic, pharmacokinetic-pharmacodynamic modeling of aztreonam-avibactam (ATM-AVI) and joint probability of target attainment simulations for adult population","volume":"69","author":"Xie","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223064000_dkaf388-B17","doi-asserted-by":"publisher","first-page":"6137","DOI":"10.1128\/AAC.00851-12","article-title":"Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa","volume":"56","author":"Crandon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223064000_dkaf388-B18","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1080\/23744235.2025.2471822","article-title":"Comparison of the in vivo efficacy and resistance development potential between cefiderocol and ceftolozane\/tazobactam human simulated exposures against Pseudomonas aeruginosa in 72-hour murine thigh infection model","volume":"57","author":"Fouad","year":"2025","journal-title":"Infect Dis (Lond)"},{"key":"2025120206223064000_dkaf388-B19","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1128\/AAC.01989-12","article-title":"Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging Gram-negative organisms, including metallo-beta-lactamase producers","volume":"57","author":"Crandon","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223064000_dkaf388-B20","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/jac\/dkv132","article-title":"Pharmacokinetics\/pharmacodynamics of a beta-lactam and beta-lactamase inhibitor combination: a novel approach for aztreonam\/avibactam","volume":"70","author":"Singh","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025120206223064000_dkaf388-B21","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1128\/AAC.00264-16","article-title":"Successful treatment of bloodstream infection due to metallo-beta-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient","volume":"60","author":"Mojica","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223064000_dkaf388-B22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/FTD.0000000000000857","article-title":"Optimization of aztreonam in combination with ceftazidime\/avibactam in a cystic fibrosis patient with chronic Stenotrophomonas maltophilia pneumonia using therapeutic drug monitoring: a case study","volume":"43","author":"Cowart","year":"2021","journal-title":"Ther Drug Monit"},{"key":"2025120206223064000_dkaf388-B23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.idnow.2021.01.014","article-title":"Successful use of avibactam and aztreonam combination for a multiresistant Stenotrophomonas maltophilia bloodstream infection in a patient with idiopathic medullary aplasia","volume":"51","author":"Diarra","year":"2021","journal-title":"Infect Dis Now"},{"key":"2025120206223064000_dkaf388-B24","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3855\/jidc.17290","article-title":"Synergistic combination of aztreonam and ceftazidime\/avibactam against resistant Stenotrophomonas maltophilia on pancreatitis","volume":"17","author":"De Almeida Torres","year":"2023","journal-title":"J Infect Dev Ctries"},{"key":"2025120206223064000_dkaf388-B25","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/jac\/dkae058","article-title":"What are the optimal pharmacokinetic\/pharmacodynamic targets for beta-lactamase inhibitors? A systematic review","volume":"79","author":"Assefa","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025120206223064000_dkaf388-B26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/jac\/dkac425","article-title":"Phenotypes, genotypes and breakpoints: an assessment of beta-lactam\/beta-lactamase inhibitor combinations against OXA-48","volume":"78","author":"Asempa","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025120206223064000_dkaf388-B27","doi-asserted-by":"publisher","first-page":"988725","DOI":"10.3389\/fmicb.2022.988725","article-title":"Expert workshop summary: advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections","volume":"13","author":"Arrazuria","year":"2022","journal-title":"Front Microbiol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3431\/64952735\/dkaf388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3431\/64952735\/dkaf388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:22:40Z","timestamp":1764674560000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3431\/8303490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf388","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,27]]}}}